Marcadores inflamatórios de instabilidade da placa aterosclerótica coronária : caraterização e potencial utilização clínica

RESUMO:Introdução: Reviu-se o conhecimento epidemiológico, fisiopatológico e clínico atual sobre a doença coronária, da sua génese até ao evento agudo, o Enfarte Agudo do Miocárdio (EAM). Valorizou-se, em especial, a teoria inflamatória da aterosclerose, que foi objeto de grandes desenvolvimentos na última década. Marcadores de instabilidade da placa aterosclerótica coronária: Aprofundou-se o conhecimento da placa aterosclerótica coronária instável. Descreveram-se detalhadamente os biomarcadores clínicos e laboratoriais associados à instabilidade da placa, com particular ênfase nos mecanismos inflamatórios. Objetivos:Estão divididos em dois pontos fundamentais:(1) Estudar em doentes com EAM a relação existente entre as moléculas inflamatórias: Interleucina-6 (IL-6), Fator de Necrose Tumoral-α (TNF-α) e Metaloproteinase de Matriz-3 (MMP3), não usados em contexto clínico, com um marcador inflamatório já em uso clínico: a Proteína C-Reativa ultrassensível (hs-CRP). Avaliar a relação de todas as moléculas inflamatórias com um biomarcador de lesão miocárdica: a Troponina Cardíaca I (cTnI). (2) Avaliar, no mesmo contexto de EAM, a Resposta de Fase Aguda (RFA) . Pretende-se demonstrar o impacto deste fenómeno, com repercussão clínica generalizada, no perfil lipídico e nos biomarcadores inflamatórios dos doentes. Métodos:(1) Estudo observacional prospetivo de doentes admitidos consecutivamente por EAM (grupo EAM) numa única unidade coronária, após exclusão de trauma ou infeção. Doseamento no sangue periférico, na admissão, de IL-6, TNF-α, MMP3, hs-CRP e cTnI. Este último biomarcador foi valorizado também nos valores séricos obtidos 6-9 horas depois. Procedeu-se a correlação linear (coeficiente de Pearson, de Rho-Spearman e determinação do R2) entre os 3 marcadores estudados com os valores de hs-CRP e de cTnI (valores da admissão e 6 a 9 horas após). Efetuou-se o cálculo dos coeficientes de regressão linear múltipla entre cTnI da admissão e cTnI 6-9h após, com o conjunto dos fatores inflamatórios estudados. (2) Estudo caso-controlo entre o grupo EAM e uma população aleatória de doentes seguidos em consulta de cardiologia, após exclusão de eventos cardiovasculares de qualquer território (grupo controlo) e também sem infeção ou trauma. Foram doseados os mesmos marcadores inflamatórios no grupo controlo e no grupo EAM. Nos dois grupos dosearam-se, ainda, as lipoproteínas: Colesterol total (CT), Colesterol HDL (HDLc), com as suas subfrações 2 e 3 (HDL 2 e HDL3), Colesterol LDL oxidado (LDLox),Triglicéridos (TG), Lipoproteína (a) [Lp(a)], Apolipoproteína A1 (ApoA1), Apolipoproteína B (ApoB) e Apolipoproteína E (ApoE). Definiram-se, em cada grupo, os dados demográficos, fatores de risco clássicos, terapêutica cardiovascular e o uso de anti-inflamatórios. Procedeu-se a análise multivariada em relação aos dados demográficos, fatores de risco e à terapêutica basal. Compararam-se as distribuições destas mesmas caraterísticas entre os dois grupos, assim como os valores séricos respetivos para as lipoproteínas estudadas. Procedeu-se à correlação entre as moléculas inflamatórias e as lipoproteínas, para todos os doentes estudados. Encontraram-se os coeficientes de regressão linear múltipla entre cada marcador inflamatório e o conjunto das moléculas lipídicas, por grupo. Finalmente, efetuou-se a comparação estatística entre os marcadores inflamatórios do grupo controlo e os marcadores inflamatórios do grupo EAM. Resultados: (1) Correlações encontradas, respetivamente, Pearson, Rho-Spearman e regressão-R2: IL-6/hs-CRP 0,549, p<0,001; 0,429, p=0,001; 0,302, p<0,001; MMP 3/hsCRP 0,325, p=0,014; 0,171, p=0,202; 0,106, p=0,014; TNF-α/hs-CRP 0,261, p=0,050; 0,315, p=0,017; 0,068, p=0.050; IL-6/cTnI admissão 0,486, p<0,001; 0,483, p<0,001; 0,236, p<0,001; MMP3/cTnI admissão 0,218, p=0,103; 0,146, p=0,278; 0,048, p=0,103; TNF-α/cTnI admissão 0,444, p=0,001; 0,380, p=0,004; 0,197, p=0,001; IL-6/cTnI 6-9h 0,676, p<0,001; 0,623, p<0,001; 0,456, p<0,01; MMP3/cTnI 6-9h 0,524, p=0,001; 0,149, p=0,270; 0,275, p<0,001; TNF-α/cTnI 6-9h 0,428, p=0,001, 0,452, p<0,001, 0,183, p<0,001. A regressão linear múltipla cTnI admissão/marcadores inflamatórios produziu: (R=0,638, R2=0,407) p<0,001 e cTnI 6-9h/marcadores inflamatórios (R=0,780, R2=0,609) p<0,001. (2) Significância da análise multivariada para idade (p=0,029), IMC>30 (p=0.070), AAS (p=0,040) e grupo (p=0,002). Diferenças importantes entre as distribuições dos dados basais entre os dois grupos (grupo controlo vs EAM): idade (47,95±11,55 vs 68,53±2,70 anos) p<0.001; sexo feminino (18,18 vs 22,80%) p=0,076; diabetes mellitus (9,09% vs 36,84%) p=0,012; AAS (18,18 vs 66,66%) p<0,001; clopidogrel (4,54% vs 66,66%) p=0,033; estatinas (31,81% vs 66,14%) p=0,078; beta-bloqueadores (18,18% vs 56,14%) p=0,011; anti-inflamatórios (4,54% vs 33,33%) p=0,009. Resultados da comparação entre os dois grupos quanto ao padrão lipídico (média±dp ou mediana/intervalo interquartil, grupo controlo vs EAM): CT (208,45±35,03 vs 171,05±41,63 mg/dl) p<0,001; HDLc (51,50/18,25 vs 42,00/16,00 mg/dl) p=0,007; HDL2 (8,50/3,25 vs 10,00/6,00 mg/dl) p=0,292; HDL3 (41,75±9,82 vs 31,75±9,41 mg/dl) p<0,001; LDLox (70,00/22,0 vs 43,50/21,00 U/L) p<0,001; TG (120,00/112,50 vs 107,00/86,00 mg/dl) p=0,527; Lp(a) (0,51/0,73 vs 0,51/0,50 g/L) p=0,854; ApoA1 (1,38±0,63 vs 1,19±0,21 g/L) p=0,002; ApoB (0,96±0,19 vs 0,78±0,28 g/L) p=0,004; ApoE (38,50/10,00 vs 38,00/17,00 mg/L) p=0,574. Nas correlações lineares entre as variáveis inflamatórias e as variáveis lipídicas para todos os doentes, encontrámos uma relação negativa entre IL-6 e CT, HDLc, HDL3, LDLox, ApoA1 e ApoB. A regressão múltipla marcadores inflamatórios/perfil lipídico (grupo controlo) foi: hs-CRP (R=0,883, R2=0,780) p=0,022; IL-6 (R=0,911, R2=0,830) p=0,007; MMP3 (R=0,498, R2=0,248) p=0,943; TNF-α (R=0,680, R2=0,462) p=0,524. A regressão múltipla marcadores inflamatórios/perfil lipídico (grupo EAM) foi: hs-CRP (R=0,647, R2=0,418) p=0,004; IL-6 (R=0,544, R2=0,300), p=0,073; MMP3 (R=0,539, R2=0,290) p=0,089; TNF-α (R=0,595; R2=0,354) p=0,022. Da comparação entre os marcadores inflamatórios dos dois grupos resultou (mediana/intervalo interquartil, grupo controlo vs EAM): hs-CRP (0,19/0,27 vs 0,42/2,53 mg/dl) p=0,001, IL-6 (4,90/5,48 vs 13,07/26,41 pg/ml) p<0,001, MMP3 (19,70/13,70 vs 10,10/10,40 ng/ml) p<0,001;TNF-α (8,67/6,71 vs 8,26/7,80 pg/dl) p=0,805. Conclusões: (1) Nos doentes com EAM, existe correlação entre as moléculas inflamatórias IL-6, MMP3 e TNF-α, quer com o marcador inflamatório hs-CRP, quer com o marcador de lesão miocárdica cTnI. Esta correlação reforça-se para os valores de cTnI 6-9 horas após admissão, especialmente na correlação múltipla com o grupo dos quatro marcadores inflamatórios. (2) IL-6 está inversamente ligada às lipoproteínas de colesterol; hs-CRP e IL-6 têm excelentes correlações com o perfil lipídico valorizado no seu conjunto. No grupo EAM encontram-se níveis séricos mais reduzidos para as lipoproteínas de colesterol. Para TNF-α não foram encontradas diferenças significativas entre os grupos, as quais foram observadas para a IL-6 e hs-CRP (mais elevadas no grupo EAM). Os valores de MMP3 no grupo controlo estão mais elevados. ABSTRACT: 0,524, p=0,001; 0,149, p=0,270; 0,275, p<0,001; TNF-α/cTnI 6-9h 0,428, p=0,001, 0,452, p<0,001, 0,183, p<0,001. A regressão linear múltipla cTnI admissão/marcadores inflamatórios produziu: (R=0,638, R2=0,407) p<0,001 e cTnI 6-9h/marcadores inflamatórios (R=0,780, R2=0,609) p<0,001. (2) Significância da análise multivariada para idade (p=0,029), IMC>30 (p=0.070), AAS (p=0,040) e grupo (p=0,002). Diferenças importantes entre as distribuições dos dados basais entre os dois grupos (grupo controlo vs EAM): idade (47,95±11,55 vs 68,53±2,70 anos) p<0.001; sexo feminino (18,18 vs 22,80%) p=0,076; diabetes mellitus (9,09% vs 36,84%) p=0,012; AAS (18,18 vs 66,66%) p<0,001; clopidogrel (4,54% vs 66,66%) p=0,033; estatinas (31,81% vs 66,14%) p=0,078; beta-bloqueadores (18,18% vs 56,14%) p=0,011; anti-inflamatórios (4,54% vs 33,33%) p=0,009. Resultados da comparação entre os dois grupos quanto ao padrão lipídico (média±dp ou mediana/intervalo interquartil, grupo controlo vs EAM): CT (208,45±35,03 vs 171,05±41,63 mg/dl) p<0,001; HDLc (51,50/18,25 vs 42,00/16,00 mg/dl) p=0,007; HDL2 (8,50/3,25 vs 10,00/6,00 mg/dl) p=0,292; HDL3 (41,75±9,82 vs 31,75±9,41 mg/dl) p<0,001; LDLox (70,00/22,0 vs 43,50/21,00 U/L) p<0,001; TG (120,00/112,50 vs 107,00/86,00 mg/dl) p=0,527; Lp(a) (0,51/0,73 vs 0,51/0,50 g/L) p=0,854; ApoA1 (1,38±0,63 vs 1,19±0,21 g/L) p=0,002; ApoB (0,96±0,19 vs 0,78±0,28 g/L) p=0,004; ApoE (38,50/10,00 vs 38,00/17,00 mg/L) p=0,574. Nas correlações lineares entre as variáveis inflamatórias e as variáveis lipídicas para todos os doentes, encontrámos uma relação negativa entre IL-6 e CT, HDLc, HDL3, LDLox, ApoA1 e ApoB. A regressão múltipla marcadores inflamatórios/perfil lipídico (grupo controlo) foi: hs-CRP (R=0,883, R2=0,780) p=0,022; IL-6 (R=0,911, R2=0,830) p=0,007; MMP3 (R=0,498, R2=0,248) p=0,943; TNF-α (R=0,680, R2=0,462) p=0,524. A regressão múltipla marcadores inflamatórios/perfil lipídico (grupo EAM) foi: hs-CRP (R=0,647, R2=0,418) p=0,004; IL-6 (R=0,544, R2=0,300), p=0,073; MMP3 (R=0,539, R2=0,290) p=0,089; TNF-α (R=0,595; R2=0,354) p=0,022. Da comparação entre os marcadores inflamatórios dos dois grupos resultou (mediana/intervalo interquartil, grupo controlo vs EAM): hs-CRP (0,19/0,27 vs 0,42/2,53 mg/dl) p=0,001, IL-6 (4,90/5,48 vs 13,07/26,41 pg/ml) p<0,001, MMP3 (19,70/13,70 vs 10,10/10,40 ng/ml) p<0,001;TNF-α (8,67/6,71 vs 8,26/7,80 pg/dl) p=0,805. Conclusões: (1) Nos doentes com EAM, existe correlação entre as moléculas inflamatórias IL-6, MMP3 e TNF-α, quer com o marcador inflamatório hs-CRP, quer com o marcador de lesão miocárdica cTnI. Esta correlação reforça-se para os valores de cTnI 6-9 horas após admissão, especialmente na correlação múltipla com o grupo dos quatro marcadores inflamatórios. (2) IL-6 está inversamente ligada às lipoproteínas de colesterol; hs-CRP e IL-6 têm excelentes correlações com o perfil lipídico valorizado no seu conjunto. No grupo EAM encontram-se níveis séricos mais reduzidos para as lipoproteínas de colesterol. Para TNF-α não foram encontradas diferenças significativas entre os grupos, as quais foram observadas para a IL-6 e hs-CRP (mais elevadas no grupo EAM). Os valores de MMP3 no grupo controlo estão mais elevados. ------------- ABSTRACT: Introduction: We reviewed the epidemiology, pathophysiology and current clinical knowledge about coronary heart disease, from its genesis to the acute myocardial infarction (AMI). The inflammatory theory for atherosclerosis, which has undergone considerable development in the last decade, was especially detailed. Markers of coronary atherosclerotic vulnerable plaque: The clinical and laboratory biomarkers associated with the unstable coronary atherosclerotic plaque vulnerable plaque are detailed. An emphasis was placed on the inflammatory mechanisms. Objectives: They are divided into two fundamental points: (1) To study in AMI patients, the relationship between the inflammatory molecules: Interleukin-6 (IL-6), Tumor Necrosis Factor-α (TNF-α) and Matrix metalloproteinase-3 (MMP3), unused in the clinical setting, with an inflammatory marker in clinical use: ultrasensitive C-reactive protein (hs-CRP), as well as a biomarker of myocardial injury: cardiac troponin I (cTnI). (2) To study, in the context of AMI, the Acute Phase Response (APR). We intend to demonstrate the impact of that clinical relevant phenomenon in the lipid profile and inflammatory biomarkers of our patients. Methods: (1) Prospective observational study of patients consecutively admitted for AMI (AMI group) in a single coronary care unit, after exclusion of trauma or infection. A peripheral assay at admission for IL-6, TNF-α, MMP3, hs-CRP and cTnI was performed. The latter was also valued in assays obtained 6-9 hours after admission. Linear correlation (Pearson's correlation coefficient, Spearman Rho's correlation coefficient and R2 regression) was performed between the three markers studied and the values of hs-CRP and cTnI (on admission and 6-9 hours after admission). Multiple linear regression was also obtained between cTnI on admission and 6-9h after, with all the inflammatory markers studied. (2) Case-control study between the AMI group and a random population of patients from an outpatient cardiology setting (control group). Cardiovascular events of any kind and infection or trauma were excluded in this group. The same inflammatory molecules were assayed in control and AMI groups. The following lipoproteins were also assayed: total cholesterol (TC), HDL cholesterol (HDLc) and subfractions 2 and 3 (HDL2 and HDL 3), oxidized LDL cholesterol (oxLDL), Triglycerides (TG), Lipoprotein (a) [Lp(a)], Apolipoprotein A1 (apoA1), Apolipoprotein B (ApoB) and Apolipoprotein E (ApoE). Demographics, classical risk factors, cardiovascular therapy and the use of anti-inflammatory drugs were appreciated in each group. The authors conducted a multivariate analysis with respect to demographics, risk factors and baseline therapy. The distribution of the same baseline characteristics was compared between the two groups, as well as the lipoprotein serum values. A correlation was performed between each inflammatory molecule and each of the lipoproteins, for all the patients studied. Multiple linear regression was determined between each inflammatory marker and all the lipid molecules per group. Finally, the statistical comparison between the inflammatory markers in the two groups was performed. Results: (1) The correlation coefficients recorded, respectively, Pearson, Spearman's Rho and regression-R2, were: IL-6/hs-CRP 0.549, p <0.001; 0.429, p=0.001; 0.302, p <0.001; MMP 3/hsCRP 0.325, p=0.014; 0.171, p=0.202; 0.106, p=0.014; TNF-α/hs-CRP 0.261, p=0.050; 0.315, p=0.017; 0.068, p=0.050; IL-6/admission cTnI 0.486, p<0.001; 0.483, p<0.001; 0.236, p<0.001; MMP3/admission cTnI 0.218, p=0.103; 0.146, p=0.278; 0.048, p=0.103; TNF-α/admission cTnI 0.444, p=0.001; 0.380, p=0.004; 0.197, p=0.001; IL-6/6-9 h cTnI 0.676, p<0.001; 0.149, p<0.001; 0.456, p <0.01; MMP3/6-9h cTnI 0.428, p=0.001; 0.149, p<0.001; 0.183, p=0.001; TNF-α/6-9 h cTnI 0.676, p<0,001; 0.452, p<0.001; 0.183, p<0,001. The multiple linear regression admission cTnI/inflammatory markers produced: (R=0.638, R2=0.407) p<0.001 and 6-9 h cTnI/inflammatory markers (R=0.780, R2=0.609) p<0.001. (2) Significances of the multivariate analysis were found for age (p=0.029), IMC>30 (p=0.070), Aspirin (p=0.040) and group (p=0.002). Important differences between the baseline data of the two groups (control group vs AMI): age (47.95 ± 11.55 vs 68.53±12.70 years) p<0.001; gender (18.18 vs 22.80%) p=0.076; diabetes mellitus (9.09% vs 36. 84%) p=0.012; Aspirin (18.18 vs. 66.66%) p<0.001; Clopidogrel (4, 54% vs 66.66%) p=0.033; Statins, 31.81% vs 66.14%, p=0.078, beta-blockers 18.18% vs 56.14%, p=0.011; anti-inflammatory drugs (4.54% vs 33.33%) p=0.009. Significant differences in the lipid pattern of the two groups (mean±SD or median/interquartile range, control group vs AMI): TC (208.45±35.03 vs 171.05±41.63 mg/dl) p<0.001; HDLc (51.50/18.25 vs 42.00/16.00 mg/dl) p=0.007; HDL2 (8.50/3.25 vs 10.00/6.00 mg/dl) p=0.292; HDL3 (41.75±9.82 vs 31.75±9.82 mg/dl) p<0.01; oxLDL (70.00/22.0 vs 43.50/21.00 U/L) p <0.001; TG (120.00/112.50 vs 107.00/86.00 mg/dl) p=0.527; Lp(a) (0.51/0.73 vs 0,51/0.50 g/L) p=0.854; apoA1 (1.38±0.63 vs 1.19±0.21 g/L) p=0.002; ApoB (0.96± 0.39 vs 0.78±0.28 g/L) p=0.004; ApoE (38.50/10,00 vs 38.00 /17,00 mg/L) p=0.574. In the linear correlations between inflammatory variables and lipid variables for all patients, we found a negative relationship between IL-6 and TC, HDLc, HDL3, ApoA1 and ApoB. The multiple linear regression inflammatory markers/lipid profile (control group) was: hs-CRP (R= 0.883, R2=0.780) p=0.022; IL6 (R=0.911, R2=0.830) p=0.007; MMP3 (R=0.498, R2=0.248) p=0.943; TNF-α (R=0.680, R2=0.462) p=0.524. For the linear regression inflammatory markers/lipid profile (AMI group) we found: hs-CRP (R=0.647, R2=0.418) p=0.004; IL-6 (R=0.544, R2=0.300) p=0.073; MMP3 (R=0.539, R2 =0.290) p=0.089; TNF-α (R=0.595, R2=0.354) p=0.022. The comparison between inflammatory markers in both groups (median/interquartile range, control group vs AMI) resulted as: hs-CRP (0.19/0.27 vs 0.42/2.53 mg/dl) p=0.001; IL-6 (4.90/5.48 vs 13.07/26.41 pg/ml) p<0.001; MMP3 (19.70/13.70 vs 10.10/10.40 ng/ml) p<0.001; TNF-α (8.67/6.71 vs 8.26/7.80 pg/dl) p=0.805. Conclusions: (1) In AMI patients there is a correlation between the inflammatory molecules IL-6, TNF-α and MMP3 with both the inflammatory marker hs-CRP and the ischemic marker cTnI. This correlation is strengthened for the cTnI at 6-9h post admission, particularly in the multiple linear regression to the four inflammatory markers studied. (2) IL-6 correlates negatively with the cholesterol lipoproteins. Hs-CRP and IL-6 are strongly correlated to the whole lipoprotein profile. AMI patients display reduced serum lipid levels. For the marker TNF-α no significant differences were found between groups, which were observed for IL-6 and hs-CRP (higher in the AMI group). MMP3 values are higher in the control group.

FREQUENCY OF Candida SPECIES IN A TERTIARY CARE HOSPITAL IN TRIANGULO MINEIRO, MINAS GERAIS STATE, BRAZIL

Infections by Candida species are a high-impact problem in public health due to their wide incidence in hospitalized patients. The goal of this study was to evaluate frequency, susceptibility to antifungals, and genetic polymorphism of Candida species isolated from clinical specimens of hospitalized patients. The Candida isolates included in this study were obtained from blood cultures, abdominal fluids, and central venous catheters (CVC) of hospitalized patients at the Clinical Hospital of the Federal University of Uberlândia during the period of July 2010 - June 2011. Susceptibility tests were conducted by the broth microdilution method. The RAPD-PCR tests used employed initiator oligonucleotides OPA09, OPB11, and OPE06. Of the 63 Candida isolates, 18 (28.5%) were C. albicans, 20 (31.7%) were C. parapsilosis complex species, 14 (22.2%) C. tropicalis, four (6.4%) C. glabrata, four (6.4%) C. krusei, two (3.3%) C. kefyr, and one (1.6%) C. lusitaniae. In vitro resistance to amphotericin B was observed in 12.7% of isolates. In vitroresistance to azoles was not detected, except for C. krusei. The two primers, OPA09 and OPB11, were able to distinguish different species. Isolates of C. albicans and C. parapsilosis complex species presented six and five clusters, respectively, with the OPA09 marker by RAPD-PCR, showing the genetic variability of the isolates of those species. It was concluded that members of the C. parapsilosis complex were the most frequent species found, and most isolates were susceptible to the antifungals amphotericin B, flucozanole, and itraconazole. High genetic polymorphisms were observed for isolates of C. albicans and C. parapsilosis complex species, mainly with the OPA09 marker.

A copper protein and a cytochrome bind at the same site on bacterial cytochrome c peroxidase

Biochemistry, 2004, 43 (46), pp 14566–14576 DOI: 10.1021/bi0485833

Anticorpos Anti-Receptor da TSH na Doença de Graves

Neste trabalho os AA avaliam a sensibilidade, especificidade e valor predictivo do doseamen to dos anticorpos anti-receptor da TSH (TRAb) no diagnóstico da doença de Graves. A população estudada incluiu 80 doentes com doença de Graves recentemente diagnosticada e sem tratamento prévio (grupo 1), 63 doentes com outras patologias tiroideias (grupo II) e 60 indivíduos sem patologia tiroideia (grupo III). Utilizaram uma técnica de radioreceptor, o kit TRAK Henning, que considera positividade> 14 U TRAb L, negatividade 9 e zona cinzenta entre estes 2 valores. No grupo 1, 11 doentes tinham TRAb negativo e 7 situavam-se na zona cinzenta. No grupo II apenas 2 doentes tinham TRAb de 9 e todos os indivíduos do grupo controlo tinham TRAb negativo. Para efeito estatístico foram excluidos os doentes com valores na zona cinzenta. Os valores de sensibilidade e especificidade para o método ensaiado foram respectivamente de 84,5° o e 10000. O valor predictivo foi de 1000 o, o que permite afirmar com segurança que um doente com hipertiroidismo e TRAb positivo tem doença de Graves.

Ocular Pulse Amplitude and Doppler Waveform Analysis in Glaucoma Patients

PURPOSE: To determine the correlation between ocular blood flow velocities and ocular pulse amplitude (OPA) in glaucoma patients using colour Doppler imaging (CDI) waveform analysis. METHOD: A prospective, observer-masked, case-control study was performed. OPA and blood flow variables from central retinal artery and vein (CRA, CRV), nasal and temporal short posterior ciliary arteries (NPCA, TPCA) and ophthalmic artery (OA) were obtained through dynamic contour tonometry and CDI, respectively. Univariate and multiple regression analyses were performed to explore the correlations between OPA and retrobulbar CDI waveform and systemic cardiovascular parameters (blood pressure, blood pressure amplitude, mean ocular perfusion pressure and peripheral pulse). RESULTS: One hundred and ninety-two patients were included [healthy controls: 55; primary open-angle glaucoma (POAG): 74; normal-tension glaucoma (NTG): 63]. OPA was statistically different between groups (Healthy: 3.17 ± 1.2 mmHg; NTG: 2.58 ± 1.2 mmHg; POAG: 2.60 ± 1.1 mmHg; p < 0.01), but not between the glaucoma groups (p = 0.60). Multiple regression models to explain OPA variance were made for each cohort (healthy: p < 0.001, r = 0.605; NTG: p = 0.003, r = 0.372; POAG: p < 0.001, r = 0.412). OPA was independently associated with retrobulbar CDI parameters in the healthy subjects and POAG patients (healthy CRV resistance index: β = 3.37, CI: 0.16-6.59; healthy NPCA mean systolic/diastolic velocity ratio: β = 1.34, CI: 0.52-2.15; POAG TPCA mean systolic velocity: β = 0.14, CI 0.05-0.23). OPA in the NTG group was associated with diastolic blood pressure and pulse rate (β = -0.04, CI: -0.06 to -0.01; β = -0.04, CI: -0.06 to -0.001, respectively). CONCLUSIONS: Vascular-related models provide a better explanation to OPA variance in healthy individuals than in glaucoma patients. The variables that influence OPA seem to be different in healthy, POAG and NTG patients.

C-reactive protein in early risk assessment in acute pancreatitis

ABSTRACT:C-reactive protein (CRP) has been widely used in the early risk assessment of patients with acute pancreatitis (AP), but unclear aspects about its prognostic accuracy in this setting persist. This project evaluated first CRP prognostic accuracy for severity, pancreatic necrosis (PNec), and in-hospital mortality (IM) in AP in terms of the best timing for CRP measurement and the optimal CRP cutoff points. Secondly it was evaluated the CRP measured at approximately 24 hours after hospital admission (CRP24) prognostic accuracy for IM in AP individually and in a combined model with a recent developed tool for the early risk assessment of patients with AP, the Bedside Index for Severity in AP (BISAP). Two single-centre retrospective cohort studies were held. The first study included 379 patients and the second study included 134 patients. Statistical methods such as the Hosmer-Lemeshow goodness-of-fit test, the area under the receiver-operating characteristic curve, the net reclassification improvement, and the integrated discrimination improvement were used. It was found that CRP measured at approximately 48 hours after hospital admission (CRP48) had a prognostic accuracy for severity, PNec, and IM in AP better than CRP measured at any other timing. It was observed that the optimal CRP48 cutoff points for severity, PNec, and IM in AP varied from 170mg/l to 190mg/l, values greater than the one most often recommended in the literature – 150mg/l. It was found that CRP24 had a good prognostic accuracy for IM in AP and that the cutoff point of 60mg/l had a negative predictive value of 100%. Finally it was observed that the prognostic accuracy of a combined model including BISAP and CRP24 for IM in AP could perform better than the BISAP alone model. These results might have a direct impact on the early risk assessment of patients with AP in the daily clinical practice.--------- RESUMO: A proteina c-reactiva (CRP) tem sido largamente usada na avaliação precoce do risco em doentes com pancreatite aguda (AP), mas aspectos duvidosos acerca do seu valor prognóstico neste contexto persistem. Este projecto avaliou primeiro o valor prognóstico da CRP para a gravidade, a necrose pancreática (PNec) e a mortalidade intra-hospitalar (IM) na AP em termos do melhor momento para efectuar a sua medição e dos seus pontos-de-corte óptimos. Em segundo lugar foi avaliado o valor prognóstico da proteína c-reactiva medida aproximadamente às 24 horas após a admissão hospitalar (CRP24) para a IM na AP isoladamente e num modelo combinado, que incluiu uma ferramenta de avaliação precoce do risco em doentes com AP recentemente desenvolvida, o Bedside Index for Severity in Acute Pancreatitis (BISAP). Dois estudos unicêntricos de coorte retrospectivo foram realizados. O primeiro estudo incluiu 379 doentes e o segundo estudo incluiu 134 doentes. Metodologias estatísticas como o teste de Hosmer-Lemeshow goodness-of-fit, a area under the receiver-operating characteristic curve, o net reclassification improvement e o integrated discrimination improvement foram usadas. Verificou-se que a CRP medida às 48 horas após a admissão hospitalar (CRP48) teve um valor prognóstico para a gravidade, a PNec e a IM na AP melhor do que a CRP medida em qualquer outro momento. Observou-se que os pontos de corte óptimos da CRP48 para a gravidade, a PNec e a IM na AP variaram entre 170mg/l e 190mg/l, valores acima do valor mais frequentemente recomendado na literatura – 150mg/l. Verificou-se que a CRP medida aproximadamente às 24 horas após a admissão hospitalar (CRP24) teve um bom valor prognóstico para a IM na AP e que o ponto de corte 60mg/l teve um valor preditivo negativo de 100%. Finalmente observou-se que o valor prognóstico de um modelo combinado incluindo o BISAP e a CRP24 para a IM na AP pode ter um desempenho melhor do que o do BISAP isoladamente. Estes resultados podem ter um impacto directo na avaliação precoce do risco em doentes com AP na prática clínica diária.

Prevalence of HIV-1/2, HTLV-I/II, hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among prison inmates at Manhuaçu, Minas Gerais State, Brazil

The purpose of this study was to determine the seroprevalence of human immunodeficiency virus (HIV-1/2), human T-cell lymphotropic virus (HTLV-I/II), hepatitis B virus (HBV), hepatitis C virus (HCV), Treponema pallidum and Trypanosoma cruzi among 63 male prisoners in Manhuaçu, Minas Gerais, Brazil and to compare this with data from eligible blood donors. The positive results were as follows: 11/63 (17.5%) for HBV, 5/63 (7.4%) for syphilis, 4/63 (6.3%) for HCV, 3/63 (4.8%) for Chagas' disease, 2/63 (3.2%) for HIV-1/2 and 1/63 (1.6%) for HTLV-I/II. The seroprevalence in prisoners was higher than among blood donors, mainly for antibodies to HIV-1/2, HCV and HBV. This is probably due to low social economic level, illiteracy, higher proportion with a prior history of intravenous drug use and/or unsafe sexual behavior. Therefore, these prisoners constitute a high risk group and routine screening and counseling are recommended.

Densidades de plantio e cultivares de soja convencionais para a região Sul de MG, safra 2013/14.

Objetivou-se identificar a melhor população de plantas (100.000 a 400.000 plantas ha-1) para 3 cultivares de soja convencional (BRSMG 752S; BRSMG 772S; BRSMG 810C), visando semeadura para região Sul de Minas Gerais. A cv BRSMG 772S apresentou máxima produtividade quando conduzida com 284.000 plantas ha-1, podendo ser cultivada entre 200.000 a 400.000 plantas ha-1. A variação na população de plantas não alterou o rendimento e a maioria dos caracteres agronômicos para as cultivares BRSMG 752S e BRSMG 810C, podendo as mesmas serem utilizadas com ampla faixa de população.

Fatores associados às formas evolutivas graves da infecção crônica pelo vírus da hepatite C

Com o objetivo de descrever os fatores epidemiológicos e clínicos-laboratoriais e avaliar os fatores associados ao desenvolvimento de fibrose moderada e grave, realizou-se a revisão de 426 prontuários médicos de pacientes com infecção crônica pelo vírus da hepatite C, atendidos na Clínica de Moléstias Infecciosas e Parasitárias da Faculdade de Medicina da Universidade de São Paulo, no período de 01/01 a 31/12/2000. Dos pacientes incluídos no estudo, 56,3% eram do sexo masculino e 43,7% do sexo feminino. A idade deles variou de 18 a 69 anos. A hemotransfusão foi a forma mais freqüente de transmissão do vírus da hepatite C, encontrada em 128 (30%) dos casos e em 187 (43,9%) pacientes não foi encontrado nenhum fator de risco. A distribuição dos pacientes quanto à alteração arquitetural visto na biópsia hepática foi: grau 0 (14,1%), grau 1 (51,2%), grau 2 (20,6%), grau 3 (8%) e grau 4 (6,1%). Na análise multivariada, encontramos associação positiva entre intensidade da fibrose e idade maior que 40 anos na data da biópsia hepática, níveis séricos de albumina abaixo do limite inferior normal, gama-glutamiltransferase maior ou igual a duas vezes o limite superior da normalidade, plaquetas em número menor que 150.000/mm³ e alta atividade necro-inflamatória. Os dados foram inconclusivos para testar a associação entre gravidade da fibrose e alcoolismo.

Epidemiological profile of hepatitis C in blood donors at the Uberaba Regional Blood Center

The aim of the present study was to outline the serological profile of hepatitis C among blood donors seen at the Uberaba Regional Blood Center, Hemominas Foundation, over the last 14 years. The frequency of hepatitis C was compared between first-time and repeat donors and the epidemiological characteristics of those with positive and indeterminate ELISA anti-HCV (third and fourth generation) were analyzed based on the donor histories kept in the archives of the Uberaba Regional Blood Center. The serological ineligibility rate was 0.3%, with higher prevalence in the group of first-time donors. We did not find any significant differences regarding age, skin color, marital status or place of residence between eligible and ineligible donors; however, the frequency of positive serology was higher among men. The lower (0.3%) rate of ineligibility due to hepatitis C that was observed at the Uberaba Regional Blood Center, in relation to most Brazilian blood centers, is probably due to the large number of repeat donors (83.3%). This reinforces the importance of achieving donor commitment for increasing transfusion safety.

Hepatitis C: sexual or intrafamilial transmission? Epidemiological and phylogenetic analysis of hepatitis C virus in 24 infected couples

The role of sexual or intrafamilial transmission of hepatitis C is controversial. A phylogenetic analysis was performed on the non-structural region 5B of the hepatitis C virus (NS5B-HCV). High percentages of homology (mean of 98.3%) were shown between the couples. Twenty (83.3%) of the 24 men but only two of the women (8.3%) reported having had sexually transmitted diseases during their lives. The risk factors for HCV acquisition were blood transfusion (10 couples), use of illegal injected drugs (17), use of inhalants (15), acupuncture (5) and tattoos (5). The shared use of personal hygiene items included toothbrushes between six couples (25%), razor blades between 16 (66.7%), nail clippers between 21 (87.5%) and manicure pliers between 14 (58.3%). The high degree of similarity of the hepatitis C virus genome supports the hypothesis of hepatitis C virus transmission between these couples. The shared use of personal hygiene items suggests the possibility of intrafamilial transmission of infection.

Indeterminate RIBA results were associated with the absence of hepatitis C virus RNA (HCV-RNA) in blood donors

Introduction: Hepatitis C virus (HCV) infection is diagnosed by the presence of antibodies and is supplemented by confirmatory testing methods, such as recombinant immunoblot assay (RIBA) and HCV-RNA detection. This study aimed to evaluate the efficacy of RIBA testing to diagnose HCV infection in blood donors positive for anti-HCV antibodies. Methods: A total of 102 subjects positive for anti-HCV determined by enzyme-linked immunosorbent assay (ELISA) at the Hematology and Hemotherapy Foundation of Bahia (HEMOBA) were later assessed with new samples using the Abbott Architect anti-HCV test (Abbott Diagnostics, Wiesbaden, Germany), the RIBA III test (Chiron RIBA HCV 3.0 SIA, Chiron Corp., Emeryville, CA, USA), the polymerase chain reaction (PCR; COBAS® AMPLICOR HCV Roche Diagnostics Corp., Indianapolis, IN, USA) and line probe assay (LiPA - Siemens, Tarrytown, NY, USA) genotyping for HCV diagnosis. Results: Of these new samples, 38.2% (39/102) were positive, 57.8% (59/102) were negative and 3.9% (4/102) were indeterminate for anti-HCV; HCV-RNA was detected in 22.5% (23/102) of the samples. RIBA results were positive in 58.1% (25/43), negative in 9.3% (4/43) and indeterminate in 32.6% (14/43) of the samples. The prevailing genotypes were 1 (78.3%, 18/23), 3 (17.4%, 4/23) and 2 (4.3%, 1/23). All 14 samples with indeterminate RIBA results had undetectable viral loads (detection limit ≤50 IU/mL). Of these samples, 71.4% (10/14) were reevaluated six months later. Eighty percent (8/10) of these samples remained indeterminate by RIBA, and 20% (2/10) were negative. Conclusions: In this study, individuals with indeterminate RIBA results had no detectable HCV-RNA.

Chagas disease: morbidity profile in an endemic area of Northeastern Brazil

Abstract: INTRODUCTION : This study evaluated the clinical forms and manifestation severities of Chagas disease among serologically reactive individuals from Western Rio Grande do Norte (Northeastern Brazil). METHODS : This cross-sectional study included 186 adults who were evaluated using electrocardiography, echocardiography, chest radiography, and contrast radiography of the esophagus and colon. A clinical-epidemiological questionnaire was also used. RESULTS : The indeterminate, cardiac, digestive, and cardiodigestive clinical forms of Chagas disease were diagnosed in 51.6% (96/186), 32.2% (60/186), 8.1% (15/186) and 8.1% (15/186) of the participants, respectively. Heart failure (functional classes I-IV) was detected in 7.5% (14/186) of the participants, and 36.4% (24/66), 30.3% (20/66), 15.2% (10/66), 13.6% (9/66), and 4.5% (3/66) of the patients were at stage A, B1, B2, C, and D, respectively. Dilated cardiomyopathy and electrocardiographic changes were detected in 10.2% (19/186) and 48.1% (91/186) of the participants, respectively. Apical aneurysm was diagnosed in 10.8% (20/186) of the participants, and other changes in the segmental myocardial contractility of the left ventricle were diagnosed in 33.9% (63/186) of the participants. Megaesophagus (groups I-IV) was observed in 7% (13/186) of the participants, megacolon (grades 1-3) was detected in12.9% (24/186) of the participants, and both organs were affected in 29.2% (7/24) of the megacolon cases. CONCLUSIONS : We detected various clinical forms of Chagas disease (including the digestive form). Our findings indicate that clinical symptoms alone may not be sufficient to exclude or confirm cardiac and/or digestive damage, and the number of patients with symptomatic clinical forms may be underestimated.

Production and characterization of Chitin-Glucan Complex by Komagataella pastoris

This thesis was focused on the production, extraction and characterization of chitin:β-glucan complex (CGC). In this process, glycerol byproduct from the biodiesel industry was used as carbon source. The selected CGC producing yeast was Komagataella pastoris (formerly known as Pichia pastoris), due the fact that to achieved high cell densities using as carbon source glycerol from the biodiesel industry. Firstly, a screening of K. pastoris strains was performed in shake flask assays, in order to select the strain of K. pastoris with better performance, in terms of growth, using glycerol as a carbon source. K. pastoris strain DSM 70877 achieved higher final cell densities (92-97 g/l), using pure glycerol (99%, w/v) and in glycerol from the biodiesel industry (86%, w/v), respectively, compared to DSM 70382 strain (74-82 g/l). Based on these shake flask assays results, the wild type DSM 70877 strain was selected to proceed for cultivation in a 2 l bioreactor, using glycerol byproduct (40 g/l), as sole carbon source. Biomass production by K. pastoris was performed under controlled temperature and pH (30.0 ºC and 5.0, respectively). More than 100 g/l biomass was obtained in less than 48 h. The yield of biomass on a glycerol basis was 0.55 g/g during the batch phase and 0.63 g/g during the fed-batch phase. In order to optimize the downstream process, by increasing extraction and purification efficiency of CGC from K. pastoris biomass, several assays were performed. It was found that extraction with 5 M NaOH at 65 ºC, during 2 hours, associated to neutralization with HCl, followed by successive washing steps with deionised water until conductivity of ≤20μS/cm, increased CGC purity. The obtained copolymer, CGCpure, had a chitin:glucan molar ratio of 25:75 mol% close to commercial CGC samples extracted from A. niger mycelium, kiOsmetine from Kitozyme (30:70 mol%). CGCpure was characterized by solid-state Nuclear Magnetic Resonance (NMR) spectroscopy and Differential Scanning Calorimetry (DCS), revealing a CGC with higher purity than a CGC commercial (kiOsmetine). In order to optimize CGC production, a set of batch cultivation experiments was performed to evaluate the effect of pH (3.5–6.5) and temperature (20–40 ºC) on the specific cell growth rate, CGC production and polymer composition. Statistical tools (response surface methodology and central composite design) were used. The CGC content in the biomass and the volumetric productivity (rp) were not significantly affected within the tested pH and temperature ranges. In contrast, the effect of pH and temperature on the CGC molar ratio was more pronounced. The highest chitin: β-glucan molar ratio (> 14:86) was obtained for the mid-range pH (4.5-5.8) and temperatures (26–33 ºC). The ability of K. pastoris to synthesize CGC with different molar ratios as a function of pH and temperature is a feature that can be exploited to obtain tailored polymer compositions.(...)

Caracterização química parcial das sementes de Lecythis pisonis camb. (Sapucaia)

Estudou-se a composição química de amêndoas do fruto da sapucaia (Lecythis pisonis Camb), provenientes da Estação Experimental de Santa Rita do Passa Quatro (SP), do Instituto Florestal de São Paulo. As análises químicas foram realizadas segundo as "Normas Analíticas do Instituto Adolfo Lutz (1985). Os resultados obtidos mostraram altos teores lipídicos (63,5 g/100g), protéicos (19,9 g/l00g), vitamina C (17,1 mg/100g) e valor calórico de 684 Kcal/100g. A fração oleosa apresentou um perfil de ácido graxos e índice de iodo (113,5), equivalente ao do óleo de milho comestível, destacando-se o ácido linoléico (48,6 % p/p) considerado como ácido graxo essencial e participante nos processos de inibição de germinação de sementes. O perfil de ácidos graxos do óleo das amêndoas de sapucaia, os teores de lipídios e de proteína foram semelhantes aos das amêndoas de castanhas-do-Pará (Bertholletia excelsa), espécie da mesma família da sapucaia, cultivada na Amazônia. Para a determinação dos nutrientes, as amostras foram tratadas por via úmida (H2SO4 e H2O2), através da radiação de microondas por sistema aberto de digestão e quantificadas por Espectrometria de Emissão Atômica com Plasma de Argônio Induzido (ICP-AES). A espécie revelou teores elevados para Na (49,8 mg/g); K (46,4 mg/g); B (64,5 mg/g); Mn (91,0 ųg/g); Fe (14,2 ųg/g) e Al (4,91 ųg/g). Entretanto, o nível de Pb encontrado (0,96 ųg/g), está acima do limite máximo permitido pela legislação brasileira (0,5 ųg/g), evidenciando uma possível toxicidade da amostra e contaminação antrópica do local amostrado.